First-line PD-1/PD-L1 inhibitor plus chemotherapy vs chemotherapy alone for negative or < 1% PD-L1-expressing metastatic non-small-cell lung cancers
- 04.11.2019
- Original Article – Clinical Oncology
Erschienen in:
- Verfasst von
- Thierry Landre
- Gaetan Des Guetz
- Kader Chouahnia
- Cherifa Taleb
- Alain Vergnenègre
- Christos Chouaïd
- Erschienen in
- Journal of Cancer Research and Clinical Oncology | Ausgabe 2/2020
Abstract
Aims
Single-agent anti-PD-1/PD-L1 clinical efficacy against < 1% PD-L1-expressing non-small-cell lung cancers (NSCLCs) is controversial.
Methods
This meta-analysis examined randomized-trial data comparing first-line PD-1/PD-L1-inhibitor + chemotherapy (CT) vs CT alone for advanced < 1% PD-L1 NSCLCs. Outcome measures included overall survival (OS), progression-free survival (PFS) and objective response rate (ORR).
Results
IMpower (atezolizumab + CT), Keynote (pembrolizumab + CT) and CheckMate (nivolumab + CT) trials included 2037 NSCLCs (1246 PD-L1–negative; 791 < 1% PD-L1 expression). Anti-PD-1/PD-L1 + CT was significantly associated (hazard ratio [95% confidence interval]) with prolonged OS (0.75 [0.63–0.89]; p = 0.0008) and PFS (0.72 [0.65–0.80]; p < 0.0001), and higher ORR (odds ratio 2.06 [1.50–2.83]; p < 0.0001).
Conclusions
First-line anti-PD-1/PD-L1 + CT combination appears superior to CT alone for advanced, < 1% PD-L1-expressing NSCLCs for OS, PFS and ORR.
Anzeige
- Titel
- First-line PD-1/PD-L1 inhibitor plus chemotherapy vs chemotherapy alone for negative or < 1% PD-L1-expressing metastatic non-small-cell lung cancers
- Verfasst von
-
Thierry Landre
Gaetan Des Guetz
Kader Chouahnia
Cherifa Taleb
Alain Vergnenègre
Christos Chouaïd
- Publikationsdatum
- 04.11.2019
- Verlag
- Springer Berlin Heidelberg
- Erschienen in
-
Journal of Cancer Research and Clinical Oncology / Ausgabe 2/2020
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335 - DOI
- https://doi.org/10.1007/s00432-019-03070-3
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.
